Drug Pipeline

Relacorilant 150 mg once daily (QD) Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
3
Recruiting
2
Top Sponsors
Active Studies by Phase
Phase 2
4
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05726292 A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus… Prostate Cancer Recruiting
NCT06906341 Relacorilant in Combination With Different Treatment Regimens in Patients With… Ovarian Cancer Recruiting
NCT07259317 Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic… Adenocarcinoma Recruiting
NCT03604198 Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With… Cushing Syndrome Active, Not Recruiting
Sponsors Running Relacorilant 150 mg once daily (QD) Trials
Corcept Therapeutics (3) University of Chicago (1)
Disease Areas
Prostate Cancer (1) Ovarian Cancer (1) Endometrial Cancer (1)
Get alerts when Relacorilant 150 mg once daily (QD) trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free